OncLive.com· @OncLive · X·· 2 days agoScore70
Body · original
Perioperative pembrolizumab plus neoadjuvant chemo did not improve EFS vs placebo plus chemo in pts w/ cisplatin-eligible MIBC undergoing radical cystectomy with pelvic lymph node dissection, according to KEYNOTE-866. @myESMO #ESMO2026 #blcsm #oncology
https://www.onclive.com/view/pembrolizumab-plus-chemo-misses-efs-end-point-in-cisplatin-eligible-mibc
311 views · 3 likes · 0 reposts · 0 replies
Conference abstracts
4735Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.orgSource: OncLive.com · x.com